Company ProfilePremium

Insecticides India Ltd.

Company Profile Analysis

Ticker: INSECTICID.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Insecticides India Ltd. - Company showcase

Year Founded & Workforce

1996

1,531 Employees

Insecticides India Ltd. logo

Insecticides India Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Insecticides India Ltd. Overview

Insecticides (India) Limited is a Delhi-headquartered, promoter-controlled, fully integrated Indian crop-protection company. It describes itself as a crop protection and nutrition company. It manufactures more than 20 technical-grade active ingredients and more than 130 branded formulations across insecticides, herbicides, fungicides, biologicals and plant-growth regulators. These are sold mainly under the four-decade-old "Tractor Brand" through 8,500+ distributors and about 70,000 retailers, reaching an estimated 7.5 million farmers. FY2026 revenue was INR 2,140 crore. That makes IIL a mid-tier domestic generics-plus-specialty player, roughly the size of Dhanuka Agritech and smaller than Rallis, PI, UPL or Bayer CropScience India. Its strategy rests on three levers. The first is "premiumisation": in-licensed patented molecules from Nissan Chemical (Japan) and Corteva Agriscience (USA), branded "Maharatna". The second is backward integration into technicals at Chopanki and Dahej. The third is an FMCG-style rural distribution model. Its main vulnerabilities are monsoon dependence, a long working-capital cycle, and a modest export base (~5% of sales).


What the company does

IIL develops, registers, manufactures and markets agrochemicals for Indian farmers, with a smaller institutional and export business. The value chain runs from technical synthesis (making the active ingredient) through formulation (turning the active ingredient into usable liquids, powders and granules), branding, distribution and farmer extension. The company says about 95% of its revenue comes from products it manufactures itself (Q1 FY27 investor presentation).

Company's own description (paraphrased from FY26/Q1 FY27 disclosures)

The company calls itself one of India's leading fully integrated crop protection and nutrition companies. It cites a portfolio of 20+ technical products and 130+ formulations, ownership of the "Tractor Brand", plants at Chopanki (Rajasthan), Samba and Udhampur (Jammu & Kashmir) and Dahej (Gujarat), and an upcoming facility at Sotanala (Rajasthan). It highlights technical synthesis plants at Chopanki and Dahej as a backward-integration advantage. It also describes in-house R&D, farmer education through the IIL Foundation, and a pan-India reach of 7.5 million+ farmers, 70,000+ dealers and 8,500+ distributors (Press Release, Q1 FY27, 11 Aug 2026).

Business model and revenue model

Revenue channelDescriptionShare of FY2026 revenueEconomics
B2C (branded formulations)Branded crop-protection products sold through the distributor → retailer → farmer chain under Tractor Brand and sub-brands73%Highest gross margin; premium sub-portfolio (Focus Maharatna + Maharatna) equals 58% of B2C
B2B (institutional)Sale of technicals and bulk formulations to other agrochemical formulators and marketers22%Lower margin; used to absorb plant capacity and meet top-line goals in weak B2C seasons
ExportsTechnicals and formulations to ~22 countries on the back of ~182 international registrations, including from a 100% export-oriented SEZ formulation unit at Dahej5%Early-stage; management targets ~10% share over 2–3 years

Revenue model characterisation: About 100% product sales. There is no material service, subscription or licensing revenue. In-licensing runs the other way: IIL pays partners such as Nissan and Corteva for the rights to market their molecules. In-licensed product revenue was about INR 46 crore in Q1 FY27 versus about INR 36 crore in Q1 FY26 (Q1 FY27 earnings call, per secondary summaries).

Product category mix (B2C revenue, FY2026)

CategoryShareFunction
Insecticides49%Insect control in crops
Herbicides37%Weed prevention and control
Fungicides10%Fungal disease control
Biologicals / PGR4%Crop health and productivity

Customer types and end-markets

End-users: Smallholder and mid-size Indian farmers growing paddy, wheat, cotton, maize, soybean, chilli, pulses, vegetables and horticulture crops.

Direct customers: About 8,500 distributors (B2C), Indian and global agrochemical companies (B2B), and importers and distributors in about 22 countries (exports).

Seasonality: Revenue is heavily skewed to the kharif (monsoon) season. Q1 (Apr–Jun) and Q2 (Jul–Sep) together produced about 62% of FY2026 revenue (INR 1,329 crore of INR 2,140 crore).

Independent characterisation

IIL is best described as a branded-generics domestic formulator that is moving into in-licensed specialty molecules and selective backward integration. It does not discover proprietary molecules at scale, unlike PI Industries or the multinationals. Its OAT Agrio JV is a discovery effort, but it has no disclosed commercial new chemical entity yet. Its competitive moat is distribution depth and brand familiarity in north and central India, plus cost advantage from captive technicals. The strategic thesis since FY2023 has been margin repair through mix. Gross margin rose from 23.1% (FY23) to 31.5% (FY26) as the premium share of B2C climbed from 51% to 58%. The thesis faced a stress test in FY2026–Q1 FY27: weather-driven demand weakness forced a higher B2B mix, and management cut guidance.

Strategy

Stated strategy themes (paraphrased from the Q1 FY27 deck and FY26 calls)

Pillar / shiftContent
Innovative product portfolioPremiumisation; aggressive launches; patented and in-licensed chemistries
Brand equity & farmer connectTractor Brand; ICS plots; field days; digital farmer campaigns
FMCG-like distribution8,500+ distributors, 70,000+ retailers, 750+ sales and marketing staff, 1,200+ crop advisors
Manufacturing prowessIntegrated technical + formulation; ~95% in-house revenue
Complete crop solutionCrop-based portfolio building (rice, cotton, chilli, soybean, maize, wheat)
Enhanced market presenceKaeros as second channel; exports

The company frames its strategy around four "fundamental pillars" and six "internal shifts":

Forward-looking themes in the deck: innovation edge, diversified growth engines (international collaborations, Kaeros, global business), global expansion, operational excellence, a business model less dependent on rainfall, and disciplined value creation.

Strategic initiatives (last 24 months)

InitiativeDateDetailStatus
Corteva Agriscience collaborationAug 2025 onwardSPARCLE (Aug 2025), GRANUVIA (May 2026), Spinoace (Q1 FY27)Active; GRANUVIA FY27 target about INR 20 crore gross
Nissan Chemical partnership extensionMay 2025Altair paddy herbicideActive
Kaeros Research acquisitionNov 2024Independent dealer channel; direct imports; Dr Dada brandManagement targeted ~INR 100 crore business in FY27 and 5–8% of volumes
Dahej capacity expansionCommercial June 2025~INR 150 crore capex; management expected ~INR 100 crore revenue contribution in FY26Ramping
Sotanala greenfield2025–2027Fully automated formulation + technical plant; ~INR 200 crore totalFormulation ~Oct–Nov 2026; technical ~Mar–Apr 2027
DigitalisationFY24–FY26IIL 360, IIL Pariwar, IIL Humsafar CRM; IIL GrowSmart learningImplemented
Demand generationFY2610,000+ demos; 26,000+ farmer meetings; 6,500+ field days; 1,45,000+ farmer visits on field daysOngoing; Q1 FY27: 3,600+ meetings, 600+ field days, 1,400 demos, 15,000+ farmer visits
ICS programme expansionFY27Double from 36 plots; 4 crops; 14 statesAnnounced Aug 2026
Capital allocation disciplineQ3–Q4 FY26Non-essential capex frozen; investment decisions gated on ROCE/ROE; maintenance capex INR 25–30 crore after FY27 projectsActive
Working-capital reductionFY25–FY27Earlier target to cut cycle 20–25 days; FY27 finance-cost reduction target 25–30%Not yet achieved (FY26 NWC 168 days)
ESPS 2026May 2026Up to 2,00,000 shares for employeesPending shareholder approval
SustainabilityFY26~40% renewable energy; ZLD at 3 plants; Project Green Miyawaki forestsOngoing

Management guidance and medium-term targets

TargetOriginalRevised / latestSource
FY26 revenue growth~10% (double-digit ambition)5–6%; actual 7%Q4 FY25 call; ~Feb 2026 revision
FY26 premium (B2C) growth≥20%~10%Same
FY26 operating margin~9% (per TradeBrains summary)~7%Same; actual EBITDA margin 10.6% (definitions differ)
Premium share of B2C65% within 1–2 years (stated FY25)58% in FY26; 64% in Q1 FY27Calls; deck
New launches≥6 per year>25 in three yearsCalls
Exports share~10% in 2–3 years5% (FY26)Q4 FY26 call
FY27 top-line and bottom-linePositive growth, double-digit volume ambitionQ1 FY27 down 12% / 24%; management "confident of progressively building momentum"Q4 FY26 call; Q1 FY27 PR
FY27 finance costsDown 25–30%—Q1 FY27 commentary (secondary)
Maintenance capex post-FY27INR 25–30 crore a year—Q4 FY26 call

Products & Services

IIL markets 130+ formulations and 20+ technicals. Not every SKU is publicly described. Products are listed below where a public source names them. Active ingredients are given only where verified; otherwise "not disclosed in sources reviewed".

Master brand

BrandDescriptionNotes
Tractor BrandUmbrella trademark on most B2C products; brand heritage since 1986; acquired 10 Mar 2003Brand campaign tagline positions it as the pride of the country and the identity of the farmer (Hindi slogan)
Dr Dada (Kaeros)Brand of Kaeros Research; positioned as the story of a young scientist who is a farmer's sonBuilt to create an independent dealer channel separate from Tractor Brand distributors

Partnership / premium launches (chronological)

ProductCategoryPartner / originLaunchTarget crop / pestKey facts
Nissan fungicide (#1 brand claim)FungicideNissan Chemical, Japan; exclusive Indian marketing rights2,012Not specified in extracted textCompany says #1 fungicide brand (management estimate)
Green LabelHerbicideMake in India; IIL makes technical and formulationPre-2016PaddyBispyribac Sodium 10% SC; first in India to manufacture both technical and formulation
Paddy herbicide (Make in India)HerbicideIIL2,016PaddyClaimed #2 in paddy herbicide category
In-house insecticideInsecticideDeveloped by IIL2,018Multi-cropClaimed top-10 in insecticides
Patented herbicide (Nissan technical collaboration)HerbicideIIL with Nissan2,021Not specifiedClaimed top-10 in herbicides
ShinwaInsecticide (premium)Nissan, Japan2,022Not specifiedMaharatna portfolio
IzukiNot specifiedNissan, Japan2,022Not specifiedLaunched with Shinwa
Patented Nissan novel insecticideInsecticideNissan; co-exclusive marketing rights in India2,022Label claim on 6 cropsClaimed top-4 in insecticides
TorryHerbicideMake in India2,022MaizeClaimed 3rd biggest corn herbicide
"Top-3 performer" Make in India productNot specifiedIIL2,022Not specifiedPer presentation
Torry SuperHerbicide (post-emergence)IIL ("SPF technology")4 Oct 2024MaizeExtension of Torry franchise
CentranInsecticideNot specified6 Jan 2025Not specifiedManagement cited it among strong FY26 performers
AltairHerbicideNissan Chemical Corporation26 May 2025PaddyFY26 launch
SPARCLEInsecticideCorteva Agriscience11 Aug 2025Paddy; brown plant hopperFirst Corteva collaboration product
GRANUVIAInsecticide (granular)Developed by Corteva Agriscience; marketed by IIL16 May 2026Paddy; brown plant hopper and stem borerAbout INR 5 crore sales in Q1 FY27; management expects ~INR 20 crore gross sales in FY27
SpinoaceInsecticideCorteva collaborationQ1 FY27Not specifiedManagement expects INR 10 crore+ in FY27

Launch cadence: More than 25 products launched in the three years to FY26 (Q4 FY26 call). Five launches in 9M FY26. The company said it had visibility to launch about five more in the 2026 kharif season.

Named brands in the generic and established portfolio

BrandCategoryPublic detail
Lethal / Lethal Super 550InsecticideMaharatna brand
HerculesInsecticideMaharatna brand
Hachiman—Maharatna brand
Pulsor—Named in company product list
Hakama—Named in company product list
KunoichiInsecticideNamed product
Mission SCInsecticideNamed product
Bheema / Bheema PlusInsecticideNamed products
MilthionInsecticideNamed product
MetacilInsecticideNamed product
TurnerInsecticideNamed product
Supremo SPInsecticideNamed product
DominantInsecticideNamed product
EncounterInsecticideNamed product
Sargent SCInsecticideNamed product
Super StarInsecticideNamed product

Brand list per ROIC.ai/S&P-derived company description and Screener. Active ingredients and specifications not disclosed in sources reviewed. Pricing for all products: not publicly disclosed. Indian agrochemicals use MRP-based retail pricing with distributor and retailer margins and seasonal schemes.

Technicals and B2B products

More than 20 technical-grade active ingredients are made at the Chopanki and Dahej multi-purpose plants (20 production streams). Individual technical molecules other than Bispyribac Sodium are not listed in reviewed sources. B2B customers buy technicals and bulk formulations.

Biologicals, PGR and nutrition

Biologicals and PGRs are about 4% of B2C. A biological unit at Shamli (Uttar Pradesh) is shown on the manufacturing map. Biological R&D covers bio-pesticides, bio-fertilisers and nano-technology products. A household-pesticide range is referenced historically in company background notes.

Services (non-revenue)

IIL Crop Solutions (ICS) programme: 36 demonstration plots across rice, cotton, chilli and soybean in 14 states. Plan is to double the number of plots.

Digital platforms: IIL 360 (field-force app), IIL Pariwar (distributor app), IIL Humsafar (retailer platform), IIL GrowSmart (employee learning).

Financial Narrative

Primary source: Q1 FY27 investor presentation (historical highlights), FY26 consolidated P&L in the same deck, Screener consolidated statements (FY22–FY25), and StockAnalysis (balance sheet and cash flow, INR million converted to crore). All figures are consolidated INR crore unless noted.

Income statement

Notes: EPS diluted equals basic; there are no material dilutive instruments. The ESPS 2026 is pending. FY22–FY24 DPS are derived from Screener payout ratios and the dividend record (INR 3 final dividends historically), so treat them as approximate. FY26 other income was INR 11.7 crore and associate share INR 0.3 crore.

Margin profile

Growth rates (FY2022→FY2026, derived): Revenue CAGR 9.2%; gross profit CAGR 14.2%; EBITDA CAGR 7.5%; PAT CAGR 6.8%.

Quarterly run-rate (most recent five quarters)

Q4 FY26 revenue is derived: FY26 INR 2,140.0 crore less 9M INR 1,713.75 crore. That implies about 19% YoY growth against Q4 FY25 (~INR 359 crore), matching management's comment of roughly 19% Q4 growth. One aggregator reported Q4 FY26 revenue of INR 430 crore down 15.7% YoY, which conflicts with company data and appears erroneous. Q2 FY26 EBITDA is derived from H1 FY26 EBITDA of INR 174.06 crore less Q1, giving about INR 89.5 crore (14.0%). That figure is left blank in the table because it is not directly reported. Q4 FY26 EBITDA margin of about 6.0% is per an aggregator.

Balance sheet

Notes: FY2026 total assets (~INR 2,000 crore) and equity (~INR 1,213 crore) are derived. Equity uses book value per share of about INR 416–417 × 2.91 crore shares; total assets sum the StockAnalysis components. PP&E including CWIP was INR 477 crore in FY26 versus INR 426 crore in FY25 (StockAnalysis). Goodwill is not separately material or disclosed. Debt is short-term working-capital borrowing; there is no disclosed long-term debt. Management-reported net working capital days are shown in 6.6.

Cash flow

Dividends paid are not separately verified for each year. They are small, roughly INR 6–9 crore a year, consistent with a ~INR 2–3 DPS on about 2.9–3.0 crore shares.

Ratios

ROE and ROCE are company-reported (Q1 FY27 deck); 3-year improvement: ROCE +570 bp and ROE +450 bp from FY23. ROIC is not separately disclosed; ROCE is the closest proxy.

Commentary on trends, inflections and drivers

FY2022–FY2023, the margin trough. Revenue jumped 19.8% in FY23 to INR 1,801 crore, but gross margin collapsed 330 bp to 23.1% and EBITDA margin halved to 6.8%. The drivers were a post-COVID spike in Chinese technical prices, inventory build at peak cost (inventory up INR 232 crore; OCF negative INR 11 crore), and a commodity-heavy mix where premium was only 51% of B2C. Net debt rose to INR 143 crore, the highest in the period.

FY2024–FY2025, mix-led repair. Management de-prioritised B2B, which fell from 27% to 20% of mix, and pushed Maharatna products. Gross margin expanded 650 bp in FY25 to 32.0% on flat revenue (+1.7%). PAT reached a record INR 142 crore. FY24 OCF was a strong INR 187 crore as inventory unwound. In FY25, receivables and inventory rose again (NWC days up to 172), cutting OCF to INR 93 crore, and the INR 50 crore buyback was executed.

FY2026, top-line recovery but margin plateau. Revenue grew 7% to INR 2,140 crore, against original guidance of about 10% that was later cut to 5–6%. Gross margin held near 31.5%, but EBITDA margin slipped 50 bp to 10.6%. Employee costs rose (INR 164 crore) and other expenses rose (INR 284 crore) with heavier marketing and launch spend. H2 was very weak: Q3+Q4 PAT was INR 22 crore. Finance cost more than doubled to INR 16.9 crore on higher working-capital borrowing (debt INR 157 crore), and receivables climbed to INR 487 crore as the company extended channel credit. Capex of about INR 95 crore (Dahej, Sotanala) plus OCF of INR 100 crore left free cash flow near zero.

Q1 FY27, weather shock. Revenue fell 12% YoY to INR 612 crore on a rainfall deficit and a delayed kharif. Volume was down about 13% per a ScanX call summary. Gross margin still expanded 240 bp to 31.6% through price discipline and a higher premium share of B2C (64%). EBITDA fell 20% and PAT fell 24% as fixed costs deleveraged; employee expense rose 14% YoY to INR 47.3 crore.

Key inflection to monitor: Whether Sotanala and Dahej capacity plus in-licensed launches (GRANUVIA, Spinoace, SPARCLE, Altair) can return the business to double-digit growth without further working-capital stretch. Management told investors to expect finance costs to fall 25–30% in FY27.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipHoldingRole

Insecticides (India) Limited

Parent

—

Manufacturing, marketing, exports

Kaeros Research Pvt Ltd (presented as "Kaeros Research Limited")

Wholly owned subsidiary

100%

Acquired FY25; independent dealer ecosystem and second distribution channel (brand "Dr Dada"); holds import licences and vendor approvals

IIL Biologicals Limited

Wholly owned subsidiary

100%

Biologicals platform

OAT & IIL India Laboratories Pvt Ltd

Joint venture with OAT Agrio Co. Ltd (Japan)

20%

New-molecule discovery R&D at Chopanki

IIL Overseas DMCC (Dubai)

Former WOS

100% (dissolution approved 9 Aug 2024)

Being wound up

IIL Foundation

CSR vehicle

—

Farmer education, Project Green

Revenue by Segment

Segment (INR Cr, derived)FY2024FY2025FY2026

B2C revenue (INR Cr)

1,3571,5001,562

B2B revenue (INR Cr)

511400471

Export revenue (INR Cr)

98100107

Total revenue from operations (INR Cr)

1,9662,0002,140

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2022FY2023FY2024

B2C share (%)

656869

B2B share (%)

262726

Exports share (%)

955

Segment YoY growth (%, derived)

Segment YoY growth (%, derived)FY2025FY2026

B2C growth (%)

10.54.1

B2B growth (%)

-21.717.7

Exports growth (%)

2.07.0

Revenue by Segment (%)

B2C mix (%)FY2022FY2023FY2024FY2025FY2026

Premium (Focus Maharatna + Maharatna) share of B2C (%)

5151595758

Generic share of B2C (%)

4949414342

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

B2C category share (%)

B2C category share (%)FY2022FY2023FY2024FY2025FY2026

Insecticides (%)

5345454949

Herbicides (%)

3340333737

Fungicides (%)

1111191010

Biologicals & PGR (%)

34344

Income Statement and Margin Analysis (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

1,5041,8011,9662,0002,140

Revenue growth YoY (%)

5.919.89.21.77.0

Gross profit (INR Cr)

397416501641675

EBITDA (INR Cr)

170122163221227

Depreciation & amortisation (INR Cr)

2626292936

Finance cost (INR Cr)

71311717

Profit before tax (INR Cr)

14184132193187

Net profit / PAT (INR Cr)

10763102142139

EPS basic (INR, bonus-adjusted)

36.2921.3634.5947.9847.91

Dividend per share (INR, bonus-adjusted, approx.)

23322

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (%)

26.423.125.532.031.5

EBITDA margin (%)

11.36.88.311.110.6

PBT margin (%)

9.44.76.79.78.7

Net margin (%)

7.13.55.27.16.5

Income Statement and Margin Analysis (%) (Quarterly)

Metric (INR Cr)Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Cr)

691.1637.7384.9426.3611.5

Gross profit (INR Cr)

201.7219.7—128.9193.2

EBITDA (INR Cr)

84.6—25.3—67.6

PAT (INR Cr)

58.159.110.511.743.9

Gross margin (%)

29.234.5—30.231.6

EBITDA margin (%)

12.2—6.66.011.1

Balance Sheet

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

1,3961,6961,7141,8982,000

Cash & short-term investments (INR Cr)

3620656792

Total debt (INR Cr)

5416387105157

Net debt (INR Cr)

18143223865

Shareholders' equity (INR Cr)

8709191,0141,0851,213

Other intangible assets (INR Cr)

1113141419

Inventory (INR Cr)

630862807886780

Trade receivables (INR Cr)

289296297385487

Net fixed assets ex-CWIP (INR Cr)

253263284287—

Capital work-in-progress (INR Cr)

91123142156—

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

135-1118793100

Capital expenditure (INR Cr)

6787493795

Free cash flow (INR Cr)

68-98138565

Change in inventory (INR Cr, cash impact)

31-23254-79106

Change in receivables (INR Cr, cash impact)

-39-7-3-94-101

Buyback outflow (INR Cr)

———500

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

12.46.910.113.111.4

ROCE (%)

16.710.413.617.816.1

ROA (%, derived)

7.73.76.07.57.0

Debt to equity (x, derived)

0.060.180.090.100.13

Net debt to EBITDA (x, derived)

0.111.170.140.170.29

Interest coverage EBITDA/interest (x, derived)

24.39.414.831.613.4

Asset turnover (x, derived)

1.081.061.151.051.07

Net working capital days (company)

162169151172168

Cash conversion cycle days (Screener)

181178161172—

Inventory days (Screener)

228247220238—

Debtor days (Screener)

70605570—

Payable days (Screener)

117128114136—

Revenue by Region

Geography (INR Cr, derived)FY2022FY2023FY2024FY2025FY2026

India domestic revenue (INR Cr)

1,3691,7111,8681,9002,033

Export revenue (INR Cr)

1359098100107

Geography growth YoY (%, derived)

Geography growth YoY (%, derived)FY2023FY2024FY2025FY2026

India domestic growth (%)

25.09.21.77.0

Export growth (%)

-33.48.92.07.0

Channel Details

ChannelDomesticExport

B2C

~INR 1,562 crore (100% domestic)

—

B2B

~INR 471 crore

—

Exports (technical + formulation)

—

~INR 107 crore

Capital Markets

ItemValueDate / source

Last verified close

INR 611.70

23 Sep 2026 (Anand Rathi)

52-week range

INR 525.90 – INR 787.00

Anand Rathi, Sep 2026

All-time high (post-bonus)

~INR 1,098

Jul 2025 (MarketScreener 1-yr high as of mid-2026)

1-year return

about −19.4%

Anand Rathi, 23 Sep 2026

3-year return

about +29.7% (cumulative, as reported; another snapshot on 28 Aug 2026 showed +8.7%)

Anand Rathi

5-year return

Not reliably verified for the current date. Screener showed a 27% 5-year CAGR as of mid-2025, before the 2025–26 drawdown.

Screener (dated)

YTD 2026

about −13.9% (to 4 Sep 2026)

MarketScreener

Capital Markets Data (INR) and Market Valuation

MetricJun-2025Jul-2025Aug-2025Sep-2025Oct-2025Nov-2025Dec-2025Jan-2026Feb-2026Mar-2026

Month-end close (INR)

965.701,072.55827.60748.35716.95724.20714.25590.75620.55531.45

Month-end market cap (INR Cr)

2,8103,1212,4082,1782,0862,1072,0781,7191,8061,546

Valuation Multiples

MultipleIILBasis

Market cap

~INR 1,780 crore

2.91 crore shares

Enterprise value

~INR 1,845 crore

Plus FY26 debt INR 157 crore, less cash and ST investments INR 92 crore

P/E (TTM)

~14.2x

TTM EPS INR 43.02 (FY26 47.91 − Q1FY26 19.97 + Q1FY27 15.08)

P/E (FY26)

~12.8x

FY26 EPS INR 47.91

EV/EBITDA (TTM)

~8.8x

TTM EBITDA ~INR 210 crore

EV/Sales (TTM)

~0.90x

TTM revenue ~INR 2,061 crore

P/B

~1.47x

BVPS ~INR 416

Dividend yield

~0.3%

INR 2 DPS

Dividend History

Fiscal yearDividend (INR/share)TypeNotes

FY2022

3 (pre-bonus)

Final

Record 16 Sep 2022

FY2023

3 (approx.)

Interim

Ex-date 24 Feb 2023

FY2024

2–3 (approx.)

Interim

Ex-date 10 Nov 2023

FY2025

2

Interim, treated as final

Ex-date 23 Aug 2024

FY2026

2

Interim

—

Key Events

EventDateDetail

Bonus 1:2

Apr 2015

Record date 17 Apr 2015

Bonus 1:2

Oct 2022

Record date 3 Oct 2022; 98.66 lakh shares

Buyback

Sep 2024

INR 50 crore; 5 lakh shares at INR 1,000 (tender)

Capital reduction FY2022

FY2022

—

Active buyback authorisation

—

As of Oct 2026

Credit Ratings

AgencyInstrumentRatingOutlookDate

CRISIL

Long-term bank facilities (INR 690 crore total rated)

A+

Stable

Upgraded 17 Jun 2025; reaffirmed 9 Jul 2025 and 16 Apr 2026

CRISIL

Short-term bank facilities

A1

—

Reaffirmed

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance (latest)

  • FY27: return to positive top-line and bottom-line growth, aiming for double-digit volume, with momentum "progressively building" after a weak Q1.

  • New launches: GRANUVIA (~INR 20 crore) and Spinoace (INR 10 crore+) in FY27; about five more kharif launches expected.

  • Kaeros: about INR 100 crore business target in FY27 (set in Aug 2025).

  • Finance cost down 25–30% in FY27; maintenance capex INR 25–30 crore a year once Sotanala is complete.

  • Premium mix ambition of 65% of B2C; exports to ~10% of sales in 2–3 years.

Consensus growth expectations

Not reliably available. The stale Simply Wall St consensus assumes about 14.6% revenue CAGR, which looks aggressive against the FY26 actual of 7% and Q1 FY27 at −12%.

Bull case

  1. Mix-driven earnings power: Gross margin held at 31.6% even as revenue fell 12% in Q1 FY27. If volumes normalise, EBITDA margins could return to 11–12%. On about INR 2,300 crore of revenue that would mean INR 255–275 crore of EBITDA, versus about INR 210 crore TTM.

  2. Cheap valuation: About 14x TTM P/E, about 8.8x EV/EBITDA and about 1.5x book. The stock is roughly 44% below its July 2025 high and close to its 52-week low, despite a CRISIL A+ balance sheet and 11–13% ROE.

  3. Visible capacity and pipeline catalysts: Sotanala formulation (late 2026) and technical (2027), a Corteva and Nissan launch cadence, and the Kaeros second channel offer multiple growth levers that are not priced in.

Bear case

  1. Working-capital drag erodes cash returns: NWC of 168 days, receivables up 26% and FY26 FCF of about INR 5 crore mean reported profits are not converting to cash. Further channel-credit expansion would raise credit risk.

  2. Guidance credibility gap: FY26 guidance was halved and Q1 FY27 missed sharply. Weather dependence persists despite the claim of a more resilient model.

  3. Structural margin gap versus peers: Operating margin is about 6 pp below Dhanuka. The generic and B2B mix (42% of B2C is generic; B2B was 34% of Q1 FY27) keeps IIL exposed to Chinese price deflation, and in-licensing royalties limit upside on premium products.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Nov 2026Q2 FY27 results: kharif recovery, B2B/B2C mix, receivables trajectory
Oct–Nov 2026Sotanala formulation commissioning
Rabi 2026-27Wheat-herbicide demand; ramp of Corteva products
Feb 2027Q3 FY27; FY28 guidance tone
Mar–Apr 2027Sotanala technical-plant start
May 2027FY27 results: delivery against finance-cost, Kaeros and export targets; ESPS implementation
OngoingMonsoon 2027 forecast (IMD, April 2027); Chinese technical price trends; CRISIL rating review

Concluding analyst verdict

Insecticides (India) Limited is a fundamentally sound but cyclically challenged mid-cap Indian agrochemical franchise, now going through a credibility test. Its achievements over FY2023–FY2025 are real. Gross margin rose by more than 8 percentage points, ROCE recovered from 10.4% to roughly 16–18%, and the company assembled credible partnerships with Nissan and Corteva that give it access to patented chemistry without discovery risk. The balance sheet remains conservative, with debt to equity around 0.13x and an A+ rating. The Tractor Brand and its distribution network remain hard assets that a new entrant could not easily replicate.

Two issues, however, prevent the business from earning a structurally higher valuation. The first is cash conversion. Over five years cumulative free cash flow was only about INR 170 crore, against about INR 553 crore of cumulative PAT, consumed by inventory, receivables and capex. Until net working capital falls well below 150 days, reported growth will not translate into compounding cash. The second is the volatility of earnings and guidance. The FY26 reset and the weak Q1 FY27 show that "premiumisation" has improved unit economics but has not insulated the business from monsoon swings or forced a lower-margin B2B mix.

At about 14x trailing earnings and about 1.5x book, the market is already pricing low growth, so the risk-reward looks asymmetric to the upside if FY27 delivers even modest recovery. The validation points are kharif normalisation, a scaled Corteva portfolio and the Sotanala start-up. Our synthesis is neutral-to-constructive. Conviction should be gated on three verifiable milestones by mid-2027: positive H2 FY27 PAT growth, FY27 operating cash flow above INR 150 crore, and finance costs actually falling as guided. Failure on these would confirm the bear thesis that IIL is a sub-scale, working-capital-heavy formulator whose margin gains are cyclical rather than structural.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionCategoryTenure / notes

Hari Chand (H.C.) Aggarwal

Chairman

Promoter, Executive

Founder; recognised by CropLife as an industry stalwart.

Rajesh Kumar Aggarwal

Managing Director (referred to as MD & CEO in awards)

Promoter, Executive

On board since 31 Oct 2001; age ~55 (MarketScreener). Hurun India "Excellence in Family Business" award 2025.

Sanskar Aggarwal

Whole-Time Director (Additional)

Promoter group, Executive

Appointed 28 May 2026 for 5 years, subject to shareholder approval; son of the MD

Anil Kumar Goyal

Whole-Time Director

Executive

—

Shyam Lal Bansal

Independent Director

Non-executive

—

Supratim Bandyopadhyay

Independent Director

Non-executive

—

Praveen Gupta

Independent Director

Non-executive

Woman director

Anil Kumar Bhatia

Independent Director

Non-executive

—

Executive Leadership Team

NameRoleNotes

Rajesh Kumar Aggarwal

MD

See above

Sandeep Aggarwal

Chief Financial Officer

Leads investor calls

Sandeep Kumar

Company Secretary & Chief Compliance Officer

Signatory to Aug 2026 filings

Dushyant Sood

Chief Marketing Officer

Participated in Q4 FY25 call (May 2025)

—

Chief Operating Officer

Appointed 11 Nov 2025 per MarketScreener

Board & Management Changes

DateChangeContext

11 Nov 2025

New COO appointed

Operational strengthening amid slowing growth

28 May 2026

Nikunj Aggarwal resigned as Whole-Time Director with immediate effect

Promoter-family member and KMP

28 May 2026

Sanskar Aggarwal appointed WTD (Additional), 5-year term

Next-generation succession signal

Shareholding Trend

Holder category (%)Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Promoters & promoter group (%)

72.3072.3072.3072.3072.30

Mutual funds (%)

9.079.069.068.938.93

FII / FPI (%)

4.664.514.464.504.40

Other DIIs (%)

0.650.440.340.340.34

Retail & others (%)

13.3213.6913.8513.9414.03

Major Shareholders

RankHolderSharesStake
1

Hari Chand Aggarwal (as The First Trustee, family trust)

1,88,14,302

64.66%
2

HDFC Small Cap Fund

25,98,408

8.93%
3

India Insight Value Fund

9,24,000

3.18%
4

Sanskar Aggarwal (promoter group)

4,00,000

1.37%
5

Rajesh Kumar Aggarwal (promoter)

4,00,000

1.37%
6

Hari Chand Aggarwal (The First Trustee, separate trust)

3,68,750

1.27%
7

ISEC Organics Limited (promoter group)

3,53,964

1.22%
8

Hari Chand Aggarwal (The First Trustee, separate trust)

3,00,000

1.03%
9

Hari Chand Aggarwal (The First Trustee, separate trust)

2,00,000

0.69%
10

Hari Chand Aggarwal (individual)

2,00,000

0.69%

Competitive Landscape

Competitors by Segment

SegmentNamed competitors

Domestic branded B2C formulations

Dhanuka Agritech, Rallis India (Tata), Bayer CropScience India, Sumitomo Chemical India, Crystal Crop Protection (unlisted), Best Agrolife, Coromandel International (crop protection), UPL (Advanta/UPL SAS India), FMC India, Syngenta India, BASF India, Willowood (unlisted)

Technicals / B2B

Bharat Rasayan, Meghmani Organics, Heranba Industries, India Pesticides, Astec LifeSciences, GSP Crop Science, NACL Industries

In-licensing of MNC molecules

Dhanuka (with Nissan, Bayer, others), Rallis, PI Industries (CSM-led), Sumitomo India

Exports

UPL, PI Industries, Sharda Cropchem, Meghmani, Bharat Rasayan

Peer Comparison FY2026

MetricInsecticides IndiaDhanuka AgritechRallis India

Revenue (INR Cr)

2,1402,0202,897

Revenue growth YoY (%)

7.0-0.88.8

Gross margin (%)

31.540.3—

EBITDA / operating margin (%)

10.616.812.5

PAT (INR Cr)

139287184

Net margin (%)

6.514.26.4

Company Snapshot

$247.1M

Revenue

1,531

Employees

1996

Founded

Delhi, India

Headquarters

SWOT Analysis

Strengths

  • Structural gross-margin uplift from mix: GM 23.1% (FY23) → 31.5% (FY26); 31.6% in Q1 FY27 despite −12% revenue
  • Premium portfolio scale-up: Premium share of B2C 51% (FY23) → 58% (FY26) → 64% (Q1 FY27); 15 Focus Maharatna and 39 Maharatna products
  • Backward integration: 2 technical plants; 15,800 MTPA active-ingredient capacity; ~95% in-house revenue
  • Distribution depth: 8,500+ distributors, 70,000+ retailers, 1,200+ crop advisors, 7.5 million farmer reach
  • Strong balance sheet and credit: Debt INR 157 crore against equity of about INR 1,213 crore (FY26); CRISIL A+/Stable since Jun 2025
  • Tier-1 innovation partners: Nissan (since 2012) and Corteva (since Aug 2025); in-licensed revenue up from ~INR 36 crore to ~INR 46 crore YoY in Q1
  • Shareholder-return track record: INR 50 crore buyback at INR 1,000 (Sep 2024); 1:2 bonuses in 2015 and 2022

Weaknesses

  • Long working-capital cycle: NWC 168 days (FY26); inventory INR 780 crore and receivables INR 487 crore against INR 2,140 crore revenue
  • Weak free cash flow: FCF about INR 5 crore in FY26; negative INR 98 crore in FY23
  • Margins below best-in-class peers: EBITDA 10.6% vs Dhanuka ~16.8% operating margin (FY26)
  • Earnings volatility: PAT went 107 → 63 → 102 → 142 → 139 crore over FY22–FY26; Q3+Q4 FY26 PAT only INR 22 crore
  • Guidance credibility: FY26 growth guidance cut from ~10% to 5–6%; premium guidance from 20% to 10%
  • Low export diversification: Exports ~5% of revenue; 2% in Q1 FY27
  • Thin gender diversity and family-run board: Female employees 1.72% (FY26 BRSR); 4 of 8 directors are executive promoters or executives

Opportunities

  • Corteva pipeline monetisation: GRANUVIA FY27 target ~INR 20 crore; Spinoace INR 10 crore+
  • Kaeros second channel: Management targets ~INR 100 crore business in FY27 and 5–8% of volumes
  • Sotanala capacity and automation: ~INR 200 crore investment; formulation from ~Oct–Nov 2026; technical Mar–Apr 2027
  • Export scale-up: ~182 registrations in 22 countries; target ~10% of sales in 2–3 years
  • Herbicide penetration in India: Herbicides rose to 37% of B2C; maize franchise with Torry and Torry Super
  • Financial-cost and working-capital release: Management targets 25–30% lower finance cost in FY27 (FY26 base INR 16.9 crore)

Threats

  • Monsoon variability: Q1 FY27 revenue −12% and PAT −24% attributed to rainfall deficit
  • Chinese overcapacity and price deflation: FY23 gross-margin collapse; FY26 pricing pressure cited
  • Channel credit risk: Receivables up 26% YoY in FY26 to INR 487 crore; bad-debt provisions ~INR 4.5 crore in FY26 (StockAnalysis)
  • Regulatory changes: Insecticides (Amendment) Rules 2026; risk of molecule bans
  • Partner dependence: Premium growth increasingly tied to Nissan and Corteva molecules
  • Competitive intensity: Peers Dhanuka (INR 70 crore buyback) and Rallis (FY26 PAT +47%) are investing and outperforming in the same market

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
26 May 2025Altair paddy herbicide launched with Nissan ChemicalPremium herbicide pipeline
28 May 2025Q4/FY25 results: FY25 revenue INR 2,000 crore (+2%); record PAT INR 142 crore; Q4 revenue +32%Peak-margin year
3 Jun 2025Management outlines FY26 roadmap: 6 launches, Dahej contribution, Sotanala capex, exportsBullish guidance baseline
Jun 2025Dahej expansion begins commercial productionCapacity addition
9–12 Jun 2025Systematix specialty agrochem conference and investor meetingsIR outreach
17 Jun 2025CRISIL upgrades to A+/StableLower credit risk perception
9 Jul 2025CRISIL reaffirms A+; rated bank limits raised to INR 690 crore from INR 650 croreMore working-capital headroom
11 Aug 2025SPARCLE launched with CortevaStart of Corteva partnership
13 Aug 2025Q1 FY26: revenue INR 691 crore (+5%), PAT INR 58 crore (+18%); stock falls 12%Market sceptical despite beat
19 Aug 2025Call commentary: Kaeros targeted at INR 100 crore business in FY27Kaeros scaling plan
12 Aug 202528th AGMGovernance
22 Sep 2025Added to S&P Global BMI IndexPassive flows
11 Nov 2025COO appointmentManagement depth
12 Nov 2025Q2 FY26: revenue INR 637.7 crore (+2%), gross margin 34.5%, PAT INR 59.1 crore; H1 EBITDA INR 174 crore (+8%); stock down about 3%Kharif weather headwinds
30 Jan 2026Q3 FY26: revenue INR 384.9 crore (+8% YoY), PAT INR 10.5 crore (−40%); stock −9.4% to INR 582.10; INR 2 interim dividend (record 6 Feb 2026)Margin compression on B2B mix
~2–3 Feb 2026Q3 call: guidance cut to 5–6% growth; premium growth to 10%; Q4 framed as "control and defence"Guidance reset
Mar 2026Stock hits low of about INR 525.90Multi-year de-rating
16 Apr 2026CRISIL affirms A+/StableCredit stable
16 May 2026GRANUVIA launched (Corteva)Key FY27 premium launch
28 May 2026FY26 results: revenue INR 2,140 crore (+7%), EBITDA INR 227 crore, PAT INR 139 crore (−2%); Q4 revenue +19%Top line recovers; profit flat
28 May 2026Nikunj Aggarwal resigns as WTD; Sanskar Aggarwal appointed; ESPS 2026 approvedSuccession and incentives
28 May 2026Q4 call: FY27 maintenance capex INR 25–30 crore; Sotanala timelines; cautious optimismCapex discipline
10 Jun 2026InsightX 2026 virtual investor conferenceIR outreach
Jun–Jul 2026Government notifies Insecticides (Amendment) Rules 2026 (digital licensing, e-returns) and Third Amendment Rules 2026Compliance cost and process change
11 Aug 2026Q1 FY27: revenue INR 611.5 crore (−12%), GM 31.6% (+240 bp), EBITDA INR 67.6 crore (−20%), PAT INR 43.9 crore (−24%); Spinoace launchedWeather-driven miss
11 Aug 2026Plan announced to double ICS plotsFarmer-connect investment
12 Aug 202629th AGM (virtual)–
22 Sep 2026Filing: analyst meet at Bharat Connect–Arihant Capital virtual conference on 28 Sep 2026Continued IR outreach
Oct–Nov 2026 (expected)Sotanala formulation start (~Diwali)Capacity catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Total revenue from operations rose from INR 19,660 Mn in FY2024 to INR 21,400 Mn in FY2026.
Insecticides India Ltd. — Revenue by Segment
Series (INR Mn)FY2024FY2025FY2026
Total revenue from operations19,66020,00021,400
B2C revenue13,57015,00015,620
B2B revenue5,1104,0004,710
Export revenue9801,0001,070

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Insecticides (India) Ltd — Q1 FY27 Investor Presentation and Press Release (NSE filings, 11 Aug 2026): nsearchives.nseindia.com/corporate/INSECTICID_11082026150134_STXEP30062026.pdf; nsearchives.nseindia.com/corporate/INSECTICID_11082026150515_STXPR30062026.pdf
  2. Q3 FY26 earnings presentation (BSE, 30 Jan 2026): Q2 & H1 FY25 investor presentation (BSE, 11 Nov 2024)
  3. FY2024-25 Directors' Report extracts (Arihant Capital/CMOTS: IIFL) · FY2023-24 BRSR (BSE filing) · FY2025-26 BRSR summary (ScanX)
  4. Bonus allotment filing, 6 Oct 2022 (BSE); buyback public announcement and letter of offer, Sep 2024 (BSE)
  5. FY25 audited results filing, 28 May 2025 (financialfilings.com)
  6. CRISIL rating rationales: 29 Oct 2021, 30 Dec 2022, 19 Mar 2024, 17 Jun 2025, 9 Jul 2025 (crisil.com); 16 Apr 2026 affirmation (MarketScreener news log)
  7. Screener.in (consolidated statements, ratios): StockAnalysis (income statement, balance sheet, cash flow, BOM:532851 and BOM:507717)
  8. Trendlyne and Upstox (shareholding): Bajaj Finserv (top holders) · Arihant Capital (monthly prices, bonus history) · Anand Rathi (price, valuation, 23 Sep 2026) · MarketScreener / Zonebourse (news log, officers, prices)
  9. Earnings-call summaries: Arthneeti (Q3 FY25, Q4 FY26, Q1 FY27) · AlphaStreet (Q3 FY26 transcript) · Prysm (Q4 FY26) · Multibagg.ai (Q1 FY27) · FilingReader (Q1 FY26)
  10. News: PTI via HDFC Sky (Q1 FY27) · TradeBrains (FY26 guidance cut) · HDFC Sky (Jun 2025 roadmap, Q2 FY26) · Indian Chemical News (Q1 FY27 · Rallis FY26) · Agrospectrum (Q3 FY25 · Dhanuka Q4 FY26) · ScanX (GRANUVIA, board changes, AGM, Sep 2026 analyst meet) · AngelOne / Chittorgarh (buyback)
  11. Regulatory context: ChemRadar and Simpliance (Insecticides Amendment Rules 2026)
  12. Peers: Tata Chemicals newsroom (Rallis FY26) · StockAnalysis (Dhanuka FY26)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.